Since cambinol shows no selectivity among SIRT1, SIRT2 and SIRT3, Mahajan *et al.* designed different cambinol analogues to modulate sirtuin activity for their potential use as chemotherapeutics. Cambinol analogue compound 17 (Figure 12.5A) showed selectivity for SIRT1, compound 8 (Figure 12.5C) for SIRT2 and compound 24 (Figure 12.5B) for SIRT3 *versus* SIRT1 and SIRT2. Cell viability assays using these cambinol analogues suggested that SIRT2 may be primarily responsible for the observed antilymphoma activity of these compound against B-cell lymphoma cell lines.[124]



Figure 12.5 Cambinol analogues. (A) Compound 17; (B) compound 24; and (C) compound 8.